Dose Intensity of Chemotherapy in Patients With Relapsed Hodgkin's Lymphoma Název časopisu Journal of clinical oncology

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F65269705%3A_____%2F10%3A%230000977" target="_blank" >RIV/65269705:_____/10:#0000977 - isvavai.cz</a>

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Dose Intensity of Chemotherapy in Patients With Relapsed Hodgkin's Lymphoma Název časopisu Journal of clinical oncology

Popis výsledku v původním jazyce

High-dose chemotherapy (HDCT) followed by autologous stem-cell transplantation (PBSCT) has become the standard treatment for patients with relapsed Hodgkin's lymphoma (HL). The intensity of treatment needed is unclear. This European intergroup study evaluated the impact of sequential high-dose chemotherapy (SHDCT) before myeloablative therapy. PATIENTS: Patients with histologically confirmed, relapsed HL were treated with two cycles of DHAP. In the standard arm (A), patients received myeloablative therapy with BEAM followed by PBSCT. Patients in the experimental arm (B) also received sequential cyclophosphamide, methotrexate and etoposide in high-doses before BEAM. RESULTS: Mortality was similar in both arms (20% and 18%). With a median observation time of 42 months, there was no significant difference in terms of FFTF (P = .56) and OS (P = .82) between arms.

Název v anglickém jazyce

Dose Intensity of Chemotherapy in Patients With Relapsed Hodgkin's Lymphoma Název časopisu Journal of clinical oncology

Popis výsledku anglicky

High-dose chemotherapy (HDCT) followed by autologous stem-cell transplantation (PBSCT) has become the standard treatment for patients with relapsed Hodgkin's lymphoma (HL). The intensity of treatment needed is unclear. This European intergroup study evaluated the impact of sequential high-dose chemotherapy (SHDCT) before myeloablative therapy. PATIENTS: Patients with histologically confirmed, relapsed HL were treated with two cycles of DHAP. In the standard arm (A), patients received myeloablative therapy with BEAM followed by PBSCT. Patients in the experimental arm (B) also received sequential cyclophosphamide, methotrexate and etoposide in high-doses before BEAM. RESULTS: Mortality was similar in both arms (20% and 18%). With a median observation time of 42 months, there was no significant difference in terms of FFTF (P = .56) and OS (P = .82) between arms.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

—

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2010

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Journal of clinical oncology

ISSN

0732-183X

e-ISSN

—

Svazek periodika

28

Číslo periodika v rámci svazku

34

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

7

Strana od-do

—

Kód UT WoS článku

—

EID výsledku v databázi Scopus

—